Login to Your Account


LONDON – A phase IIb placebo-controlled trial reported in The Lancet is the first to show clinical efficacy of a gene therapy in the treatment of cystic fibrosis.


Cerespir Inc. submitted a special protocol assessment (SPA) plan for the phase III trial with CSP-1103 to treat mild cognitive impairment (MCI) Alzheimer's disease (AD) – "the right drug at the right time," CEO Daniel Chain told BioWorld Today.

A phase IIb failure of sodium channel Nav1.7 inhibitor TV-45070 in osteoarthritis (OA) of the knee should have no readthrough to an ongoing phase IIb study of the topically applied small molecule in postherpetic neuralgia (PHN), executives of Xenon Pharmaceuticals Inc. assured investors Wednesday morning, citing distinct pain mechanisms between OA and neuropathic pain indications.

More IN THE CLINIC Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: